Britain’s AstraZeneca said on Thursday that good data was coming in so far on its vaccine for Covid-19, already in large-scale human trials and widely seen as the front-runner in the race for a shot against the novel coronavirus.
The drugmaker, Britain‘s most valuable listed company, also announced second quarter results that beat its sales and profit estimates, thanks to strong sales from a diverse product line-up.
“The vaccine development is progressing well. We have had good data so far. We need to show the efficacy in the clinical programme,